OncoCyte Corporation
OCX
$2.73
$0.083.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.84M | 1.88M | 709.00K | 1.02M | 1.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.84M | 1.88M | 709.00K | 1.02M | 1.38M |
| Cost of Revenue | 1.75M | 1.05M | 593.00K | 709.00K | 846.00K |
| Gross Profit | 2.09M | 828.00K | 116.00K | 314.00K | 536.00K |
| SG&A Expenses | 14.95M | 14.15M | 12.78M | 12.35M | 12.95M |
| Depreciation & Amortization | 73.00K | 88.00K | 88.00K | 88.00K | 88.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.14M | 25.13M | 23.59M | 22.66M | 23.21M |
| Operating Income | -23.30M | -23.25M | -22.88M | -21.63M | -21.83M |
| Income Before Tax | -58.21M | -60.66M | -43.14M | -36.14M | -39.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.21 | -60.66 | -43.14 | -36.14 | -39.94 |
| Earnings from Discontinued Operations | -- | -- | 0.00 | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.21M | -60.66M | -43.14M | -36.14M | -39.94M |
| EBIT | -23.30M | -23.25M | -22.88M | -21.63M | -21.83M |
| EBITDA | -21.58M | -21.68M | -21.56M | -20.22M | -20.29M |
| EPS Basic | -3.53 | -4.40 | -4.43 | -4.26 | -4.97 |
| Normalized Basic EPS | -0.89 | -1.18 | -1.35 | -1.44 | -1.62 |
| EPS Diluted | -3.53 | -4.40 | -4.43 | -4.26 | -4.97 |
| Normalized Diluted EPS | -0.89 | -1.18 | -1.35 | -1.44 | -1.62 |
| Average Basic Shares Outstanding | 69.66M | 52.23M | 43.11M | 37.66M | 32.88M |
| Average Diluted Shares Outstanding | 69.66M | 52.23M | 43.11M | 37.66M | 32.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |